The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation
Tarih
2005Yazar
So, TMK
Cakaloglu, Y
Gerken, G
Simon, C
Janssen, HLA
van Zonneveld, M
Flink, HJ
Verhey, E
Senturk, H
Zeuzem, S
Akarca, US
Schalm, SW
Hansen, BE
de Man, RA
Üst veri
Tüm öğe kaydını gösterÖzet
Background: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events.
Koleksiyonlar
- Makale [92796]